Chinese market

PhillipCapital 'remains confident' in iX Biopharma’s growth prospects upon China agreement - THE EDGE SINGAPORE

Broker's Calls

PhillipCapital 'remains confident' in iX Biopharma’s growth prospects upon China agreement

iX Biopharma remains a “buy” for PhillipCapital analyst Tay Wee Kuang, with an unchanged target price of 44.5 cents, as the specialty pharmaceutical company announced that it has entered into a str

UOBKayHian names a focus on stability and selected cyclicals as good investment strategies for 4Q2020 - THE EDGE SINGAPORE

Stocks To Watch

UOBKayHian names a focus on stability and selected cyclicals as good investment strategies for 4Q2020

UOBKayHian (UOBKH) is continuing to look at equities with a focus on high-quality companies that have a strong earnings outlook, re-opening plays, exposure to the Chinese market as well as selected

China Focus

China's coupon-led recovery

(Apr 3): Western markets have soared with the arrival of helicopter money in the US.

Commentary

Reassessment of investing strategies required as investment sands are shifting

SINGAPORE (Apr 15): Where do I allocate my long-term investment capital to maximise growth? Globalisation offered many opportunities and a means to diversify risk.

×